Hualan Biological Engineering Inc. Overview
Pro stress-test →Hualan Biological Engineering is a leading Chinese biopharmaceutical company specializing in plasma-derived products, vaccines, and recombinant biologics. Founded in 1992 and listed on the Shenzhen Stock Exchange in 2007, the company has established itself as a national high-tech enterprise with a comprehensive portfolio spanning blood products, viral vaccines, and genetic engineering products.
Strategic Profile
Pro stress-test →The company holds a strong market position in China's biopharmaceutical sector, particularly in plasma products and vaccines. With reported market capitalization around 71.6 billion CNY and revenue trends in the multi-billion CNY range, Hualan benefits from China's growing healthcare demand and government support for domestic biopharmaceutical manufacturers. The company operates with institutional backing and maintains alignment with state-owned pharmaceutical enterprises, positioning it as a strategically important player in China's healthcare ecosystem.
Competitive Landscape
Pro stress-test →Hualan competes within China's biopharmaceutical sector against other plasma product and vaccine manufacturers. The company's ownership ties to China National Pharmaceutical Group Corporation and state backing provide competitive advantages in procurement and regulatory approval. Main competitors include other Chinese plasma producers and vaccine manufacturers operating in comparable therapeutic areas, though Hualan's market share in animal vaccines (20%+ by 2015) demonstrates sectoral strength.
Industry Context
Hualan Biological Engineering Inc. operates in Biopharmaceuticals - Plasma Products & Vaccines.
Key facts
Founded: 1992 · Headquarters: Lanzhou, China · Revenue: ~1.58B CNY (latest quarter, unaudited) · Market cap: 71.6B CNY (9.27B EUR)